Explore the words cloud of the BOOSTB4 project. It provides you a very rough idea of what is the project "BOOSTB4" about.
The following table provides information about the project.
|Coordinator Country||Sweden [SE]|
|Total cost||8˙378˙755 €|
|EC max contribution||6˙608˙754 € (79%)|
1. H2020-EU.3.1. (SOCIETAL CHALLENGES - Health, demographic change and well-being)
|Duration (year-month-day)||from 2016-01-01 to 2020-12-31|
Take a look of project's partnership.
|1||KAROLINSKA INSTITUTET||SE (STOCKHOLM)||coordinator||1˙827˙061.00|
|2||GREAT ORMOND STREET HOSPITAL FOR CHILDREN NATIONAL HEALTH SERVICE TRUST||UK (LONDON)||participant||1˙410˙493.00|
|3||KLINIKUM DER UNIVERSITAET ZU KOELN||DE (KOELN)||participant||703˙132.00|
|4||UNIVERSITY COLLEGE LONDON||UK (London)||participant||648˙543.00|
|5||ACADEMISCH ZIEKENHUIS LEIDEN||NL (LEIDEN)||participant||568˙656.00|
|6||CELLPROTECT NORDIC PHARMACEUTICALS AB||SE (Huddinge)||participant||549˙781.00|
|7||EURAM LIMITED||UK (LINCOLN)||participant||281˙000.00|
|8||LUNDS UNIVERSITET||SE (Lund)||participant||241˙156.00|
|9||MEDSCINET AB||SE (Stockholm)||participant||121˙093.00|
|10||NORDIC HEALTH ECONOMICS AB||SE (GOTEBORG)||participant||106˙000.00|
|11||UNIVERSITAIR MEDISCH CENTRUM UTRECHT||NL (UTRECHT)||participant||101˙836.00|
|12||UNIVERSITY OF LEICESTER||UK (LEICESTER)||participant||50˙000.00|
Osteogenesis imperfecta (OI) is, in its severe forms, a devastating inherited disorder characterised by brittle bones. A person with severe OI is affected throughout their lifetime with repeated, multiple fractures, considerable pain and handicap. There is no curative or effective treatment for OI. Our preclinical studies and initial clinical cases have demonstrated that transplantation of fetal mesenchymal stem cells (MSC) is a promising approach for treatment of OI. We receive regular requests for MSC transplantation from patients and their physicians; patient organisations support our approach. The principal objective of the BOOSTB4 project is to conduct a Phase I/II clinical trial of the safety and efficacy of pre- and/or postnatal MSC transplantation in the severest forms of OI (type III, severe type IV). Transplantation before birth at the onset of disease should lead to greater efficacy and engraftment with less rejection than transplantation after birth. Postnatal transplantation will be evaluated in cases where prenatal diagnosis was not made. The trial’s primary outcome is safety; secondary outcomes relate to efficacy (fracture frequency, growth, bone mineral density and quality of life). All patients will undergo molecular diagnosis to confirm OI before inclusion in the trial. Non-invasive prenatal diagnosis will be developed and validated. The BOOSTB4 consortium is led by experts in MSC, prenatal therapy and OI at the Karolinska Institutet (KI), which will also lead the international multicentre trial; five additional EU centres of excellence are included. Ethical and regulatory applications are underway to conduct this clinical trial. These are facilitated by the ethical and regulatory approvals for prenatal MSC transplantation in 10 cases of OI that have already been granted at KI. Successful prenatal transplantation represents a major step forward in the management of patients with severe OI, and beyond, to a range of other inherited birth defects.
Work performed, outcomes and results: advancements report(s)
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BOOSTB4" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BOOSTB4" are provided by the European Opendata Portal: CORDIS opendata.